Author pages are created from data sourced from our academic publisher partnerships and public sources.
Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
- K. Beusterien, J. Davies, +4 authors Steve Bramham-Jones
- Health and quality of life outcomes
- 18 May 2010
BackgroundGiven that treatments for chronic lymphocytic leukaemia (CLL) are palliative rather than curative, evaluating the patient-perceived impacts of therapy is critical. To date, no utility… Expand
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
- B. Woods, N. Hawkins, W. Dunlop, A. O'Toole, Steve Bramham-Jones
- Value in health : the journal of the…
- 1 July 2012
OBJECTIVES To evaluate the cost-effectiveness of bendamustine compared with chlorambucil as first-line treatment for patients with chronic lymphocytic leukemia who would be considered unsuitable for… Expand
PCN133 POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA